Myriad Genetics, Inc. (MYGN)
After hours:
| Previous Close | 18.17 |
| Open | 18.10 |
| Bid | 18.59 x 1400 |
| Ask | 21.02 x 900 |
| Day's Range | 18.06 - 18.74 |
| 52 Week Range | 16.02 - 36.95 |
| Volume | |
| Avg. Volume | 544,251 |
| Market Cap | 1.497B |
| Beta (5Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.33 |
- GlobeNewswire
Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society. The report outlines actions taken to expand access to genetic testing, advance socia
- Zacks
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
- GlobeNewswire
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s networkPartnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company,
